Table 3 Sensitivity analysis
| Placebo (n = 57) | Quetiapine (n = 57) | OR (95% CI) | Interaction Effect, P-value | |
|---|---|---|---|---|
| Age group | ||||
| < 75 years (n = 54) | n = 28 | n = 26 |
.481 for delirium incidence 1.0 for 30-day mortality 0.057 for 90-day mortality | |
| Delirium incidence, n (%) | 3 (10.7) | 3 (11.5) | 1.09 (0.20–5.94) | |
| Mortality, n (%) | ||||
| 30 days | 2 (7.1) | 1 (3.8) | 0.52 (0.04–6.10) | |
| 90 days | 7 (25.0) | 2 (7.7) | 0.25 (0.05–1.34) | |
| ≥ 75 years (n = 60) | n = 29 | n = 31 | ||
| Delirium incidence, n (%) | 2 (6.9) | 5 (16.1) | 2.60 (0.46–14.59) | |
| Mortality, n (%) | ||||
| 30 days | 0 (0.0) | 0 (0.0) | 0.00 | |
| 90 days | 2 (6.9) | 5 (16.1) | 2.60 (0.46–14.59) | |
| Length of hospital stay | ||||
| ≤ 5 days (n = 61) | n = 35 | n = 26 |
.938 for delirium incidence .998 30-day mortality .088 for 90-day mortality | |
| Delirium incidence, n (%) | 2 (5.7) | 2 (7.7) | 1.38 (0.18–10.46) | |
| Mortality, n (%) | ||||
| 30 days | 1 (1.6) | 0 (0.0) | 0.00 | |
| 90 days | 3 (8.6) | 4 (15.4) | 1.94 (0.40–9.53) | |
| > 5 days (n = 53) | n = 22 | n = 31 | ||
| Delirium incidence, n (%) | 3 (13.6) | 6 (19.4) | 1.52 (0.34–6.87) | |
| Mortality, n (%) | ||||
| 30 days | 1 (4.5) | 1 (3.2) | 0.70 (0.04–11.83) | |
| 90 days | 6 (27.3) | 3 (9.7) | 0.29 (0.06–1.30) | |